Get the Stockscreener App
5.93
18.21%
-1.32
After Hours:
5.98
0.05
+0.84%
Transcode Therapeutics Inc stock is traded at $5.93, with a volume of 24,551.
It is down -18.21% in the last 24 hours and up +21.14% over the past month.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
See More
Previous Close:
$7.25
Open:
$6.45
24h Volume:
24,551
Relative Volume:
0.43
Market Cap:
$5.64M
Revenue:
-
Net Income/Loss:
$-40.36M
P/E Ratio:
-0.1219
EPS:
-48.648
Net Cash Flow:
$-21.40M
1W Performance:
-29.66%
1M Performance:
+21.14%
6M Performance:
-39.92%
1Y Performance:
-46.09%
1-Day Range:
$5.85
$6.69
1-Week Range:
$5.85
$8.965
52-Week Range:
$3.82
$20.99
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
5.93 | 6.89M | 0 | -40.36M | -21.40M | -48.65 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
ON: ON Semiconductor Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
TransCode Therapeutics (NASDAQ: RNAZ) investor conversion leads to 9.9% stake - Stock Titan
TransCode Therapeutics (RNAZ) Proxy Filing Summary - Quartr
TransCode Therapeutics, Inc. (RNAZ) 8-K: Key Nasdaq Approvals and Stockholder Vote Results July 2026 - Minichart
TransCode Therapeutics Shareholders Approve Key Capital Measures - TipRanks
TransCode Therapeutics (RNAZ) AGM 2026 Summary - Quartr
Frontier tech research, news & data - MLQ.ai
Form 13D/A TransCode Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
TransCode Therapeutics Updates Preferred Stock Ownership Limits - TipRanks
TransCode Therapeutics (RNAZ) investor to convert preferred stock toward 9.99% stake - Stock Titan
TransCode Therapeutics (NASDAQ: RNAZ) raises Series C ownership cap to 9.99% - Stock Titan
Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates - Kalkine
Understanding Momentum Shifts in (RNAZ) - Stock Traders Daily
Price to earnings forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Enterprise value to EBIT forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Price to book forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Price to sales forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
RNAZ | TransCode Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Avoiding Lag: Real-Time Signals in (RNAZ) Movement - Stock Traders Daily
TransCode Adjourns Annual Meeting Amid Nasdaq Listing Steps - TipRanks
Nasdaq review delays TransCode (NASDAQ: RNAZ) vote on preferred conversion - Stock Titan
TransCode Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAZ) - TradingView
TransCode Therapeutics, Inc. Actuals & Estimates (BOATS:RNAZ) - TradingView
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RNAZ Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Transcode Therapeutics Inc (RNAZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TransCode Therapeutics Inc. (RNAZ) Q4 2024 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEarnings Analysis - dars.gov.et
Discipline and Rules-Based Execution in RNAZ Response - Stock Traders Daily
TransCode Highlights Progress of Lead RNA Cancer Therapeutic - TipRanks
Transcript : TransCode Therapeutics, Inc.Special Call - marketscreener.com
TransCode Therapeutics posts investor presentation detailing Phase 1a safety, Phase 2a plan and $12.8M cash - TradingView
TransCode Therapeutics (NASDAQ: RNAZ) furnishes new investor presentation via Form 8-K - Stock Titan
Transcode Therapeutics Inc (RNAZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Institutional Confidence - TradingKey
Transcode Therapeutics Inc (RNAZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Transcode Therapeutics Inc (RNAZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcode Therapeutics Inc (RNAZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Transcode Therapeutics Inc (RNAZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TransCode Therapeutics (RNAZ) Rallies 3.27% as Biotech Stock Tests Key ResistanceFactor Crowding - newsline.com
RNAZ Technical Analysis & Stock Price Forecast - Intellectia AI
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid No RevenueAnalyst Earnings Estimate - newsline.com
Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma
Inside a new colorectal cancer trial: TransCode’s June 18 webcast with Harvard oncologist - Stock Titan
RNAZ: Introducing RNA Therapeutics - Yahoo Finance
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline DevelopmentMid-Term Outlook - newsline.com
RNAZ Q4 2024 Earnings: Wider-than-expected loss amid pre-revenue stageNet Profit Margin - newsline.com
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study - Sahm
Exclusive: TransCode's RNA therapeutic achieves 64% stable disease rate in colorectal cancer phase 1 study - MSN
TransCode Therapeutics (RNAZ) Advances to Phase 2a Following Pos - GuruFocus
RNAZ | TransCode Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):